Department of Veterinary Surgery & Radiology, West Bengal University of Animal and Fishery Sciences, Kolkata, India.
CSIR-IICB, Jadavpur, India.
Curr Eye Res. 2024 Jul;49(7):750-758. doi: 10.1080/02713683.2024.2330520. Epub 2024 Mar 19.
Systemic use of Ivermectin has been reported to incite blindness in humans and veterinary patients. This study was designed to investigate the systemic and intravitreal effect of Ivermectin on ocular and retinal health and its attenuation with topical Dexamethasone.
Systemic injection of Ivermectin@ 1.6 mg/kg S/C was administered, thrice a week for three weeks to New Zealand White rabbits ( = 4) with and without topical drops of Verapamil ( = 4). Pre and post-treatment ocular examination was conducted. At the end of three weeks the eyes were collected for histopathology.0.2 ml of Ivermectin solution (1.6 mg/ml) was injected intravitreally in one eye of the rabbit ( = 8), Half the rabbits received 0.1% dexamethasone drops thrice daily for 7 days, while the controls received PBS. Pre and post-treatment, detailed examination was conducted, which included the Schirmer Tear test, Fluorescein staining, Intraocular pressure, slit lamp biomicroscopy and fundus photography. The retina was harvested for histopathological and tunnel assay.
Systemic therapy with Ivermectin, with and without Verapamil did not incite any adverse response in the eye. Intravitreal Ivermectin evoked severe uveitis 4/4, cataract 3/4, corneal erosion 3/4 eyes and severe inflammatory response. Eyes that received dexamethasone were rescued from the adverse changes as demonstrated clinically, by histopathology and prevention of apoptosis.
Intravitreal Ivermectin incites severe inflammatory response. Topical dexamethasone counters the ocular toxicity incited by Ivermectin.
有报道称，伊维菌素的全身使用会引起人类和兽医患者失明。本研究旨在调查伊维菌素对眼部和视网膜健康的全身和玻璃体内作用，以及地塞米松局部滴眼对此作用的衰减。
给新西兰白兔（每组 4 只）皮下注射伊维菌素 1.6mg/kg，每周 3 次，共 3 周，同时给予维拉帕米（每组 4 只）滴眼。进行治疗前后的眼部检查。3 周后收集眼球进行组织病理学检查。将 0.2ml 伊维菌素溶液（1.6mg/ml）玻璃体内注射到一只兔子的眼睛（每组 8 只），其中一半兔子接受 0.1%地塞米松滴眼剂，每日 3 次，共 7 天，而对照组给予 PBS。治疗前后进行详细检查，包括 Schirmer 泪液测试、荧光素染色、眼压、裂隙灯生物显微镜检查和眼底照相。收获视网膜进行组织病理学和隧道试验。
伊维菌素全身治疗，无论是否联合维拉帕米，都没有引起眼部不良反应。玻璃体内伊维菌素引起 4/4 只眼睛严重葡萄膜炎、4/4 只眼睛白内障、3/4 只眼睛角膜侵蚀和严重炎症反应。接受地塞米松治疗的眼睛在临床上、组织病理学和预防凋亡方面均从不良反应中得到挽救。
玻璃体内伊维菌素引起严重炎症反应。局部地塞米松可对抗伊维菌素引起的眼部毒性。
